Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: A phase 2, randomised, double-blind, placebo-controlled study

The Lancet Oncology

Volumn 12, Issue 4, 2011, Pages 369-376

  Martin, Miguel ^a   Roche, Henri ^b   Pinter, Tamas ^c   Crown, John ^c   Kennedy, M John ^d   Provencher, Louise ^e   Priou, Frank ^f   Eiermann, Wolfgang ^g   Adrover, Encarna ^a   Lang, Istvan ^h   Ramos, Manuel ^a   Latreille, Jean ⁱ   Jagiełło Gruszfeld, Agnieszka ^j   Pienkowski, Tadeusz ^k   Alba, Emilio ^a   Snyder, Raymond ^l   Almel, Sachin ^m   Rolski, Janusz ⁿ   Munoz, Montserrat ^a   Moroose, Rebecca ^o   Hurvitz, Sara ^p   Baños, Ana ^q   Adewoye, Henry ^r   Hei, Yong Jiang ^r   Lindsay, Mary Ann ^s   Rupin, Matthieu ^t   Cabaribere, David ^t   Lemmerick, Yasmin ^s   Mackey, John R ^u   more..

^a Grupo Español de Investigación en Cáncer de Mama   (Spain)

^b INSTITUT CLAUDIUS REGAUD   (France)

^c Pszichiátriai Mentálhygiénés és Addiktológiai Centrum   (Hungary)

^d Ireland Cooperative Oncology Research Group ICORG   (Ireland)

^e LAVAL UNIVERSITY   (Canada)

^f Service de Reanimation Polyvalente   (France)

^g Frauenklinik Rotkreuzklinikum   (Germany)

^h Orszagos Onkologiai Inteset   (Hungary)

ⁱ HÔPITAL CHARLES LEMOYNE   (Canada)

^j Memorial Cancer Center ^*

^k INSTITUTE OF ONCOLOGY   (Poland)

^l ST VINCENT S HOSPITAL   (Australia)

^m P D HINDUJA NATIONAL HOSPITAL   (India)

ⁿ INSTITUTE OF ONCOLOGY   (Poland)

^o TORI Los Angeles   (Poland)

^p UNIVERSITY OF CALIFORNIA   (United States)

^q AMGEN LTD   (United Kingdom)

^r AMGEN INC   (United States)

^s Breast Cancer Intl Research Group   (Canada)

^t Cancer International Research Group   (France)

^u CROSS CANCER INSTITUTE   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MOTESANIB; PACLITAXEL; PLACEBO;

ABDOMINAL PAIN; ALOPECIA; ANOREXIA; ARTICLE; BACKACHE; BREAST CANCER; BREAST METASTASIS; CANCER GROWTH; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; FATIGUE; HEART LEFT VENTRICLE FAILURE; HEPATOBILIARY DISEASE; HUMAN; HYPERTENSION; INFECTION; INFESTATION; MAJOR CLINICAL STUDY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT CANCER; SENSORY NEUROPATHY; STOMATITIS; SURVIVAL RATE; SURVIVAL TIME; TREATMENT RESPONSE; VOMITING;

EID: 79953196070     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(11)70037-7     Document Type: Article

References (23)

1. Fossati R, Confalonieri C, Torri V, et al. Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women. J Clin Oncol 1998, 16:3439-3460.
2. Gasparini G Prognostic value of vascular endothelial growth factor in breast cancer. Oncologist 2000, 5(suppl 1):37-44.
3. Gasparini G, Toi M, Miceli R, et al. Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy. Cancer J Sci Am 1999, 5:101-111.
4. Gasparini G, Toi M, Gion M, et al. Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma. J Natl Cancer Inst 1997, 89:139-147.
5. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989, 246:1306-1309.
6. Genentech. Avastin (bevacizumab). Full Prescribing Information. South San Francisco, CA, 2009.
7. Miles DW, Chan A, Dirix LY, et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2010, 28:3239-3247.
8. Robert NJ, Diéras V, Glaspy J, et al. RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 2010, published online March 7. 10.1200/JCO.2010.28.0982.
9. Karaman MW, Herrgard S, Treiber DK, et al. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 2008, 26:127-132.
10. Rosen LS, Kurzrock R, Mulay M, et al. Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors. J Clin Oncol 2007, 25:2369-2376.
11. Miller KD. A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer. American Society of Clinical Oncology; Orlando, FL, USA; 2005. Presentation.
12. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007, 357:2666-2676.
13. Seidman AD, Berry D, Cirrincione C, et al. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol 2008, 26:1642-1649.
14. Gradishar WJ, Kaklamani V, Prasad Sahoo T, et al. A double-blind, randomized, placebo-controlled, phase IIb study evaluating the efficacy and safety of sorafenib (SOR) in combination with paclitaxel (PAC) as a first-line therapy in patients (pts) with locally recurrent or metastatic breast cancer (BC). 32nd Annual San Antonio Breast Cancer Symposium; San Antonio, TX, USA; Dec 9-13, 2009. Abstr 44.
15. Baselga J. Grupo Español de Estudio Tratamiento y Otras Estrategias Experimentales en Tumores Sólidos, Roché H, et al. A multinational double-blind, randomized phase IIB study evaluating the efficacy and safety of sorafenib compared to placebo when administered in combination with capecitabine in patients with locally advanced or metastatic breast cancer (BC). ECCO 15 and 34th ESMO Multidisciplinary Congress. Berlin, Sept 20-24, 2009. Abstr 5142.
16. Rugo HS, Stopeck A, Joy AA, et al. A randomized, double-blind phase II study of the oral tyrosine kinase inhibitor (TKI) axitinib (AG-013736) in combination with docetaxel (DOC) compared to DOC plus placebo (PL) in metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 2007, 25(suppl). Abstr 1003.
17. Burstein HJ, Elias AD, Rugo HS, et al. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2008, 26:1810-1816.
18. Liljegren A, Bergh J, Castany R Early experience with sunitinib, combined with docetaxel, in patients with metastatic breast cancer. Breast 2009, 18:259-262.
19. Kozloff M, Chuang E, Starr A, et al. An exploratory study of sunitinib plus paclitaxel as first-line treatment for patients with advanced breast cancer. Ann Oncol 2010, 21:1436-1441.
20. Mayer EL, Dhakil S, Patel T, et al. SABRE-B: an evaluation of paclitaxel and bevacizumab with or without sunitinib as first-line treatment of metastatic breast cancer. Ann Oncol 2010, 21:2370-2376.
21. Barrios CH, Liu M-C, Lee SC, et al. Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer. Breast Cancer Res Treat 2010, 121:121-131.
22. Bergh J, Greil R, Voytko N, et al. Sunitinib (SU) in combination with docetaxel (D) versus D alone for the first-line treatment of advanced breast cancer (ABC). J Clin Oncol 2010, 28(suppl). abstr LBA1010.
23. Crown J, Dieras V, Staroslawska E, et al. Phase III trial of sunitinib (SU) in combination with capecitabine (C) versus C in previously treated advanced breast cancer (ABC). J Clin Oncol 2010, 28(suppl). abstr LBA1011.